Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)
NCT02277132 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · PHASE2/PHASE3 · terminated · last registry update 2026-11-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Results of interim analysis” | – | Registry record, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Also stopped (terminated): Philips Clinical & Medical Affairs Global, a drug against PDE5A (NCT04696354)
- 2026-10-27Results posted on the registry: University of Florida, Tadalafil (NCT05195775)
- 2026-09-28Also stopped (suspended): University of Miami, tadalafil (NCT07636161)
- 2026-09-17Phase 3 first posted: Silvia Ulrich, Dextrose + Sildenafil 20mg (NCT07824674)
- 2026-08-28Results posted on the registry: National Jewish Health, Sildenafil 40mg oral capsule + Placebo Oral capsule (NCT04039087)
- 2026-08-12Phase 3 first posted: Ain Shams University, Tadalafil 5mg (NCT07761806)
- 2026-07-30Results posted on the registry: Vanderbilt University Medical Center, Tadalafil 20 MG + Placebo (NCT04684589)
- 2026-06-17Results posted on the registry: Respira Therapeutics, Inc., Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI) (NCT04266197)
- 2026-03-30Phase 3 first posted: Beni-Suef University, pentoxifylline 400 mg (NCT07499817)
- 2026-03-11Results posted on the registry: University of North Carolina, Chapel Hill, Sildenafil (NCT03142568)
- 2026-03-10Phase 3 first posted: Sindh Institute of Cardiovascular Diseases, Sildenafil 25 MG + Placebo (NCT07462260)
- 2026-02-23Also stopped (terminated): National Cancer Institute (NCI), nivolumab + tadalafil (NCT03785210)
- 2026-02-12Results posted on the registry: University of California, San Diego, Pembrolizumab + Tadalafil (NCT03993353)
- 2026-01-26Results posted on the registry: Christoph Hornik, Sildenafil + Placebo (NCT04447989)
- 2025-12-09Results posted on the registry: Mezzion Pharma Co. Ltd, Udenafil (NCT03013751)
- 2025-11-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tadalafil + Ambrisentan (NCT07245680)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision